HEADLINES -=6
Indian Market Indian equity markets up by 0.27% Nifty up by 16.25 pts and settle at 6009.50 Sensex up by 50.54 pts at 19764.78 Bank Nifty down by 8.65 pts at 12778.20
DAILY EQUITY NEWSLETTER 4TH JANUARY 2013
Global Market European markets were up with FTSE down by 9.43 closed at 6017,CAC down by 20.18 closed at 3713 and DAX down by 25.01 closed at 7753. Dow future was down 20.00 closed at 13311.00
HEADLINES • Offtake target bigger challenge than production: Coal India • Govt may consider ordinance for Hindustan Zinc stake sale • IGL keen to buy ADB stake in Petronet LNG • Dr Reddy's Laboratories launches hair loss tablets in US
WWW.EPICRESEARCH.CO
09752199966
MARKET ANALYSIS: The 50-unit S&P CNX Nifty moved past the psychological 6,000 level as key benchmark indices eked out small gains. The barometer index, BSE Sensex, was provisionally up 38.66 points or 0.2%, up 59.61 points from the day's low and off 33.40 points from the day's high. The market breadth, indicating the overall health of the market, was positive. Index heavyweight Reliance Industries (RIL) extended intraday gains in late trade. The BSE Sensex was up 38.66 points or 0.2% to 19,752.90. The S&P CNX Nifty was up 12.15 points or 0.2% to 6,005.40. Among the 30-share Sensex pack, 17 declined while the rest of them gained. IT pivotals rose after US lawmakers early this week reached a last-minute deal to avert the fiscal cliff. US is the biggest outsourcing market for the Indian IT firmsIT major Tata Consultancy Services rose 1.5%.India's third largest software services exporter by revenues Wipro gained 0.83%.Shares of banking giant State Bank of India (SBI) gained 0.88% to Rs 2,469.75 after striking a 52-week high of Rs 2,482.20 in intraday today, 3 January 2013. Dr Reddy's Laboratories advanced 2.35% after the company said it has launched Finasteride Tablets 1 mg in the US market.
FII’s and DII’s
STOCKS TO WATCH CROMPTON
CATEGORY
DATE
BUY
SELL
NET
ADANI
FII
3-Jan-13
3089.48
1692.11
1397.37
BHEL
DII
3-Jan-13
996.46
1902.42
-905.96
PFC
SCRIPS IN BAN PERIOD
NIFTY DAILY PIVOTS
PIVOT
R4
R3
R2
R1
PP
S1
S2
S3
S4
NIFTY
6097
6066
6035
6022
6004
5991
5973
5942
5911
WWW.EPICRESEARCH.CO
SUZLON
09752199966
.
GAINERS AND LOOSERS
EXPERT OPINION NIFTY
DAILY NIFTY GAINERS SCRIPS
RATE
VOL.
PR.
NET
%
(000)
CLOSE
CHAN
CHANG
GE
E
Dr Reddys Lab
1882.30
Cairn India
327.50
2442.67
320.00
7.50
2.34
Bharti Airtel
328.00
3677.59
321.05
6.95
2.16
ONGC
279.80
4215.38
274.60
5.20
1.89
DLF
238.90
5511.61
235.20
3.70
1.57
584.79
1837.70
44.60
Nifty looks Consolidate
Strategy: Buy on dips
Support: 5970
Resistance: 6060
2.43
BANK NIFTY
Bank Nifty looks Consolidate
Strategy: Buy on dips
Support: 12700
Resistance: 12840
.0
PREVIOUS PERFORMANCE TYPE
SCRIP
B/S
CASH
AMTEK
S
CASH
ZEE ENTERTAINMENT
B
FUTURE
ADANI ENTERPRISE
B
NOT EXECUTED
FUTURE
HCL TECHNOLOGIES
S
NOT EXECUTED
DAILY NIFTY LOOSERS SCRIPS
RATE
VOL.
PR.
NET
%
(000)
CLOSE
CHAN
CHAN
GE
GE
Tata Power
110.15
Lupin
608.85
475.31
614.90
-6.05
-0.98
PNB
896.80
587.50
905.50
-8.70
-0.96
Sun Pharma Inds.
733.85
520.44
740.90
-7.05
-0.95
Hero MotoCorp
1887.95
334.61
1905.35
-17.40
-0.91
1607.01
112.00
-1.85
-1.65
09752199966
RESULT
NOT EXECUTED TGT ACHEIVED
MARKET CALLS CASH SCRIPS
ACTION
LEVEL
1ST TARGET
2ND TARGET
STOP LOSS
BHARTI AIRTEL
BUY
328.90
330.90
333.90
326.90
ICICI BANK
SELL
1168.00
1158.00
1145.00
1178.00
TARGET
STOP LOSS
FUTURE SCRIPS
ACTION
LEVEL
ST
1
TARGET
ND
2
. ALLAHBAD BANK
BUY
181.30
182.30
183.80
180.30
ADANI ENETERPRISES
SELL
282.00
281.00
279.50
283.00
Disclaimer The information and views in this report, our website & all the service we provide are believed to be reliable, but we do not accept any responsibility (or liability) for errors of fact or opinion. Users have the right to choose the product/s that suits them the most. Sincere efforts have been made to present the right investment perspective. The information contained herein is based on analysis and up on sources that we consider reliable. This material is for personal information and based upon it & takes no responsibility The information given herein should be treated as only factor, while making investment decision. The report does not provide individually tailor-made investment advice. Epic research recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. Epic research shall not be responsible for any transaction conducted based on the information given in this report, which is in violation of rules and regulations of NSE and BSE. The share price projections shown are not necessarily indicative of future price performance. The information herein, together with all estimates and forecasts, can change without notice. Analyst or any person related to epic research might be holding positions in the stocks recommended. It is understood that anyone who is browsing through the site has done so at his free will and does not read any views expressed as a recommendation for which either the site or its owners or anyone can be held responsible for . Any surfing and reading of the information is the acceptance of this disclaimer. All Rights Reserved. Investment in equity & bullion market has its own risks. We, however, do not vouch for the accuracy or the completeness thereof. we are not responsible for any loss incurred whatsoever for any financial profits or loss which may arise from the recommendations above epic research does not purport to be an invitation or an offer to buy or sell any financial instrument. Our Clients (Paid Or Unpaid), Any third party or anyone else have no rights to forward or share our calls or SMS or Report or Any Information Provided by us to/with anyone which is received directly or indirectly by them. If found so then Serious Legal Actions can be taken.